ALNA - Allena Pharmaceuticals, Inc.
| Previous Close | 8.54 |
| Open | 8.39 |
| Bid | 8.43 x 800 |
| Ask | 16.80 x 800 |
| Day's Range | 8.39 - 9.23 |
| 52 Week Range | 6.13 - 17.56 |
| Volume | 13,073 |
| Avg. Volume | 37,600 |
| Market Cap | 178.754M |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.96 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 32.29 |
- GlobeNewswire•10 days ago
Allena Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business Update
Allena Pharmaceuticals, Inc. (ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today reported financial results for the third quarter ended September 30, 2018 and also provided a business update. “As new research emerges on oxalate’s damaging effects on the kidneys, we are encouraged by the growing awareness of enteric hyperoxaluria and widespread focus on addressing the significant burden of kidney stone disease and kidney damage that it causes.
- GlobeNewswire•11 days ago
Allena Pharmaceuticals to Present at Upcoming Investor Conferences in November
NEWTON, Mass., Nov. 06, 2018 -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage biopharmaceutical company dedicated to developing and commercializing first-in-class,.
- GlobeNewswire•23 days ago
Allena Pharmaceuticals to Present Data Characterizing Significant Unmet Need in Enteric Hyperoxaluria at ASN Kidney Week 2018
Allena Pharmaceuticals, Inc. (ALNA), a late-stage biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that it will present clinical data characterizing the significant unmet need in patients with enteric hyperoxaluria in a poster presentation at ASN Kidney Week 2018, held October 23-27, 2018 in San Diego, CA. The poster presentation includes composite data, details on kidney stone burden, and case studies from 33 patients with enteric hyperoxaluria who enrolled across Allena’s three Phase 2 clinical trials of reloxaliase (formerly ALLN-177). Data from these 33 patients confirmed that a majority experienced persistently high 24-hour urinary oxalate (UOx) excretion, despite following standard-of-care guidance for diet and hydration. Among 20 patients for whom kidney stone burden was assessed by CT scan, 16 had at least one kidney stone (KS) detected at enrollment (80%), with an average of three stones present. Additionally, 20% of patients presenting with KS had very large stones, which could require urological intervention.
- GlobeNewswire•26 days ago
Allena Pharmaceuticals Presents Preclinical Data Demonstrating Normalized Urine Uric Acid Excretion and Plasma Urate Reduction Following Treatment with ALLN-346
Allena Pharmaceuticals, Inc. (ALNA), a late-stage biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced preclinical proof-of-concept data for ALLN-346, its lead product candidate for hyperuricemia and gout in the setting of advanced chronic kidney disease (CKD). The data were presented in a poster session on Saturday, October 20, 2018 at the 2018 American College of Rheumatology (ACR/ARHP) Annual Meeting in Chicago, IL.
- GlobeNewswire•last month
Allena Pharmaceuticals Highlights Ongoing Efforts to Address Rare and Severe Metabolic Disorders Affecting the Kidney with Presentations at Upcoming Medical Meetings
NEWTON, Mass., Oct. 18, 2018 -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class,.
- GlobeNewswire•2 months ago
Allena Pharmaceuticals to Present at Upcoming Investor Conferences in October
NEWTON, Mass., Sept. 25, 2018 -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class,.
- Zacks•4 months ago
Allena Pharmaceuticals Enters Oversold Territory
Allena Pharmaceuticals has been on a bit of a cold streak lately but there might be light at the end of the tunnel for this overlooked stock.
- Simply Wall St.•7 months ago
Allena Pharmaceuticals Inc (NASDAQ:ALNA): Are Analysts Bull Or Bear?
The most recent earnings announcement Allena Pharmaceuticals Inc’s (NASDAQ:ALNA) released in December 2017 confirmed company earnings became less negative compared to the previous year’s level – great news for investorsRead More...
- Zacks•7 months ago
Allena Pharmaceuticals (ALNA) Enters Overbought Territory
Allena Pharmaceuticals, Inc. (ALNA) has moved higher as of late, but there could definitely be trouble on the horizon for this company
- Motley Fool•8 months ago
3 Biotech Stocks That Soared This Week: Are They Buys?
Can these hot stocks keep the momentum going?
- Simply Wall St.•9 months ago
Who Are The Top Investors In Allena Pharmaceuticals Inc (NASDAQ:ALNA)?
In this article, I’m going to take a look at Allena Pharmaceuticals Inc’s (NASDAQ:ALNA) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject amongRead More...
- GuruFocus.com•9 months ago
Pharmstandard International S.A. Buys Allena Pharmaceuticals Inc
Investment company Pharmstandard International S.A. buys Allena Pharmaceuticals Inc during the 3-months ended 2017-12-31, according to the most recent filings of the investment company, Pharmstandard International ...
- Simply Wall St.•last year
What Is The Future Prospect For Healthcare And Allena Pharmaceuticals Inc (ALNA)?
Allena Pharmaceuticals Inc (NASDAQ:ALNA), a USD$261.28M small-cap, is a healthcare company operating in an industry, which faces demand for new drug development to meet new or persistent chronic illnesses, andRead More...
